Cargando…

Evaluation of Plasma Neurofilament Light Chain Levels as a Biomarker of Neuronal Injury in the Active and Chronic Phases of Autoimmune Neurologic Disorders

OBJECTIVE: To evaluate plasma neurofilament light (NfL) levels in autoimmune neurologic disorders (AINDs) and autoimmune encephalitis (AE). BACKGROUND: Each particular neural autoantibody syndrome has a different clinical phenotype, making one unifying clinical outcome measure difficult to assess. W...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kammeyer, Ryan, Mizenko, Christopher, Sillau, Stefan, Richie, Alanna, Owens, Gregory, Nair, Kavita V., Alvarez, Enrique, Vollmer, Timothy L., Bennett, Jeffrey L., Piquet, Amanda L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924486/ https://www.ncbi.nlm.nih.gov/pubmed/35309573 http://dx.doi.org/10.3389/fneur.2022.689975

Ejemplares similares

A Longitudinal, Observational Analysis of Neuronal Injury Biomarkers in a Case Report of a Patient With Paraneoplastic Anti-CRMP5 Antibody-Associated Transverse Myelitis
por: Mizenko, Christopher, et al.
Publicado: (2021)

Update in autoimmune and paraneoplastic myelopathies: Newly described antigen targets and antibody testing
por: Passeri, Michlene, et al.
Publicado: (2022)

Serum neurofilament light chain levels are associated with early neurological deterioration in minor ischemic stroke
por: Li, Jie, et al.
Publicado: (2023)

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis
por: Varhaug, Kristin N., et al.
Publicado: (2019)

Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury
por: Depoorter, Antoinette, et al.
Publicado: (2018)

Evaluation of multiple consensus criteria for autoimmune encephalitis and temporal analysis of symptoms in a pediatric encephalitis cohort
por: Pointon, Tiffany, et al.
Publicado: (2022)

CSF Neurofilament Light Chain Elevation Predicts ALS Severity and Progression
por: Sun, Qionghua, et al.
Publicado: (2020)

Blood neurofilament light chain in Parkinson’s disease
por: Buhmann, Carsten, et al.
Publicado: (2023)

Evidence of polygenic regulation of the physiological presence of neurofilament light chain in human serum
por: Herrera-Rivero, Marisol, et al.
Publicado: (2023)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
por: Honce, Justin M., et al.
Publicado: (2020)

Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis
por: Vollmer, Brandi L., et al.
Publicado: (2022)

CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Natural Variation of Vitamin D and Neurofilament Light Chain in Relapsing-Remitting Multiple Sclerosis
por: Røsjø, Egil, et al.
Publicado: (2020)

Development of a Highly Sensitive Neurofilament Light Chain Assay on an Automated Immunoassay Platform
por: Lee, Stephen, et al.
Publicado: (2022)

CSF-Progranulin and Neurofilament Light Chain Levels in Patients With Radiologically Isolated Syndrome—Sign of Inflammation
por: Pawlitzki, Marc, et al.
Publicado: (2018)

Serum glial fibrillary acidic protein and neurofilament light chain in patients with early treated phenylketonuria
por: Lotz-Havla, Amelie S., et al.
Publicado: (2022)

Serum neurofilament light chain in myasthenia gravis subgroups: An exploratory cohort and case–Control study
por: Stascheit, Frauke, et al.
Publicado: (2023)

Acute Neurofilament Light Chain Plasma Levels Correlate With Stroke Severity and Clinical Outcome in Ischemic Stroke Patients
por: Nielsen, Helle H., et al.
Publicado: (2020)

Update in Autoimmune Movement Disorders: Newly Described Antigen Targets in Autoimmune and Paraneoplastic Cerebellar Ataxia
por: Garza, Madeline, et al.
Publicado: (2021)

Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases
por: Gaiottino, Johanna, et al.
Publicado: (2013)

Serum Neurofilament Light Chain Levels and Myelin Oligodendrocyte Glycoprotein Antibodies in Pediatric Acquired Demyelinating Syndromes
por: Simone, Marta, et al.
Publicado: (2021)

Cerebrospinal fluid neurofilament light chain predicts short-term prognosis in pediatric Guillain-Barré syndrome
por: Jin, Mei, et al.
Publicado: (2022)

Neurofilament levels in patients with neurological diseases: A comparison of neurofilament light and heavy chain levels
por: Kušnierová, Pavlína, et al.
Publicado: (2019)

Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
por: Krajnc, Nik, et al.
Publicado: (2022)

Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Serum Neurofilament Light Chain Levels May Be a Marker of Lower Motor Neuron Damage in Amyotrophic Lateral Sclerosis
por: Zhang, Linjing, et al.
Publicado: (2022)

Neurofilament light chain and S100B serum levels are associated with disease severity and outcome in patients with aneurysmal subarachnoid hemorrhage
por: Zhou, Zhangming, et al.
Publicado: (2022)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain
por: Gaetani, Lorenzo, et al.
Publicado: (2021)

Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Comparison of fingolimod and dimethyl fumarate in the treatment of multiple sclerosis: Two-year experience
por: Vollmer, Brandi, et al.
Publicado: (2017)

Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis
por: Gil-Perotin, Sara, et al.
Publicado: (2019)

Case Report: A 72-Year-Old Woman With Progressive Motor Weakness, Dry Eyes and High Levels of Serum Neurofilament Light Chain
por: Wendebourg, Maria Janina, et al.
Publicado: (2022)

Multiple Sclerosis Phenotypes as a Continuum: The Role of Neurologic Reserve
por: Vollmer, Timothy L., et al.
Publicado: (2021)

Neurofilament light chain in the vitreous humor of the eye
por: Subramanian, Manju L., et al.
Publicado: (2020)

Neurofilament light chain: defining the analyte
por: Leckey, Claire A., et al.
Publicado: (2022)

Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson’s disease
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder
por: Aktas, Orhan, et al.
Publicado: (2023)

Serum Creatine, Not Neurofilament Light, Is Elevated in CHCHD10-Linked Spinal Muscular Atrophy
por: Järvilehto, Julius, et al.
Publicado: (2022)

Editorial: Autoimmunity and the Brain: Paraneoplastic Neurological Injury and Beyond
por: Greenlee, John E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vl39o3204r823nqf1ma8p8prut